Applications for US jobless benefits rise modestly, but continuing claims are most in 2 years
Slightly more Americans filed for jobless claims last week, but the overall number of people in the U.S. collecting unemployment benefits rose to its highest level in two years
2023-11-30 21:56
Turn Your Controller Into a Command Center – Introducing Turtle Beach’s Groundbreaking Designed for Xbox Stealth Ultra Wireless Controller
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:56
Kroger trims annual sales view on choppy grocery demand, lower prices
(Reuters) -Kroger on Thursday cut its annual sales forecast, pinched by moderating food and grocery prices at a time when
2023-11-30 21:52
Federal Reserve's preferred inflation gauge shows price pressures continuing to cool
The Federal Reserve’s preferred inflation measure cooled last month, the latest sign that price pressures are waning in the face of high interest rates and moderating economic growth
2023-11-30 21:46
Cory Simpson Appointed CEO of Institute for Critical Infrastructure Technology (ICIT)
WASHINGTON--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:29
Lynn Smith joins National Bank of Coxsackie as VP/Chief Credit Officer
LATHAM, N.Y.--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:29
Beech-Nut Nutrition Company was Voted “Best Baby Food Brand” by 11k What to Expect Parents
AMSTERDAM, New York--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:25
Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth
LONDON--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:22
Renesas Unveils the First Generation of Own 32-bit RISC-V CPU Core Ahead of Competition
TOKYO--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:16
Thousands of fake Facebook accounts shut down by Meta were primed to polarize voters ahead of 2024
Meta says it has found and disabled thousands of fake Facebook accounts linked to China that were used to spread politically partisan content in the United States before next year’s election
2023-11-30 21:15
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
TORONTO--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 20:56
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market
2023-11-30 20:54